Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587961 | 0.97 | XDH (0.42) | PDE4APDE4BPDE4CPDE4DXDH | |
| SCHEMBL3598978 | 0.94 | XDH (0.43) | XDH | |
| SCHEMBL3585744 | 0.91 | XDH (0.49) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL3579532 | 0.90 | KDM4E (0.41) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL3584617 | 0.88 | XDH (0.50) | PDE4APDE4BPDE4CPDE4DXDH | |
| SCHEMBL3588238 | 0.87 | KDM4E (0.41) | ALDH1A1XDH | |
| SCHEMBL3583718 | 0.86 | XDH (0.42) | ALDH1A1HPGDXDH | |
| SCHEMBL3585625 | 0.86 | XDH (0.52) | XDH | |
| SCHEMBL3582223 | 0.85 | NPC1 (0.48) | ALDH1A1XDH | |
| SCHEMBL3581418 | 0.85 | XDH (0.53) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | PDE4A 1997/4885PDE4B 1577/4885PDE4C 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.